All lobbying filings

BRISTOL-MYERS SQUIBB COMPANY

BRISTOL-MYERS SQUIBB COMPANY filed a Q4 report for BRISTOL-MYERS SQUIBB COMPANY on January 20, 2026.

Lobbying for BRISTOL-MYERS SQUIBB COMPANY

All filings by BRISTOL-MYERS SQUIBB COMPANY · Everything BRISTOL-MYERS SQUIBB COMPANY has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$1,250,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

MICHAEL CALVO New on this filing

Previously held: U.S. House-Rep. Charles Taylor-LC , LA, SLA 2004 - 2007; Rep. Patrick McHenry-Policy Advisor 2007; Rep. Phil Gingrey SLA, SPA, LD, DepCoS 2007-2015; Rep. Jody Hice, LD 2015 -2016

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Health Issues

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025

Medicare/Medicaid

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act

Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Intellectual Property Reform concerning bio-pharmaceutical industry

Trade (domestic/foreign)

International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues

Bills named in this filing 3

H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 7635
The 340B PATIENTS Act of 2024

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.